Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 492 of 6351
-
Could ring fit adventures fight depression in breast cancer survivors?
Symptom relief Recruiting nowThe goal of this three arm, double-blind, randomized controlled trial is to learn if an exergame-acceptance and commitment therapy (e-ACT) program can treat depression and anxiety in breast cancer patients, compared to acceptance and commitment therapy (ACT) alone and treatment-a…
Sponsor: Universiti Sains Malaysia • Aim: Symptom relief
Last updated Jul 25, 2026 00:00 UTC
-
AI-Powered 3D scanner could spot skin cancer before it spreads
Diagnosis Not yet recruitingThe background to this research is that frequent medical screening of the general population for melanoma is not feasible. The real challenge of this project is to develop an automatic process for detecting any potential melanoma. To this end, the project aims to design an algori…
Sponsor: Assistance Publique Hopitaux De Marseille • Aim: Diagnosis
Last updated Jun 27, 2026 07:57 UTC
-
New scope surgery may improve outcomes for babies with meningitis complications
Disease control Not yet recruitingGlobally, approximately 750,000 cases of infantile meningitis occur annually\[1\]. Clinical data show infantile postmeningitis subdural fluid collection (IPSFC) is the most common complication of infantile bacterial meningitis (IBM), with a progression rate of 30-60% (39% in stan…
Sponsor: Shengjing Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Warm lung transport device aims to cut transplant failure
Disease control Not yet recruitingThis is a prospective, multicenter randomized trial of lung transplant recipients transplanted with either a DBD or DCD donor lungs. The DENOVO Trial will enroll a total of 300 patients in the OCS arm and 150 patients in the SCS arm. The primary endpoint will be patient \& graft …
Sponsor: TransMedics • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Tumor avatars could personalize sarcoma therapy
Disease control By invitation onlyThis study is a prospective single arm multicenter intervention study aimed at evaluating the feasibility of using organoid drug sensitivity results to guide first-line treatment of advanced leiomyosarcoma. The primary endpoint of the study is objective response rate (ORR). The s…
Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Heart scar on MRI may decide who gets a lifesaving shock device
Disease control Not yet recruitingResearch questions: The value of primary prevention implantable cardioverter-defibrillator implantation (ICD) therapy in patients with non-ischemic cardiomyopathy (NICM) is under debate. Improved risk stratification is needed to select patients at highest risk. Hypotheses: 1. In…
Sponsor: University Medical Center Groningen • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Could anakinra save brain tissue after a stroke? new trial aims to find out
Disease control Not yet recruitingThe investigators initiated a multicenter, prospective, randomized, open label, blinded-endpoint (PROBE) controlled trial to explore the safety and efficacy of different dose of Anakinra compared to standard medical care for patients with acute ischemic stroke who have achieved s…
Phase 2 • Sponsor: Beijing Tiantan Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New hope: interferon drug may stop deadly blood cancers from coming back after transplant
Disease control Not yet recruitingTo investigate the efficacy of interferon-α prophylaxis in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) with TP53 mutation who were negative for minimal residual disease (MRD) by flow cytometry within 2 months after allogeneic hematopoietic stem c…
Phase 2 • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New eye drug aims to match leading treatment for blinding disease
Disease control Not yet recruitingThe goal of this clinical trial is to evaluate the efficacy and safety of QL1207H injection versus aflibercept 8 mg in patients with neovascular age-related macular degeneration. The main question it aims to answer is: • Whether the efficacy and safety of QL1207H and aflibercept…
Phase 3 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New hope for rare fever disorder: drug targets stubborn cases
Disease control CancelledThe purpose of this study is to evaluate the efficacy and safety of anakinra in Chinese patients with colchicine-resistand Familial Mediterranian Fever (FMF). The study consists of up to one month screening, to see if a patient is suitable to the study, 6 months of treatment with…
Phase 4 • Sponsor: Swedish Orphan Biovitrum • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Freeze and unleash: experimental combo aims to boost immune attack on aggressive breast cancer
Disease control Not yet recruitingSummary Points: 1. High Risk Breast Cancers: Triple negative cancer is considered high risk due to high rate of local and systemic failure. Newer innovative treatment strategies are needed to improve systemic control of disease and survival. 2. Immune system modulation: is an em…
Phase 1/2 • Sponsor: Texas Tech University Health Sciences Center • Aim: Disease control
Last updated Jun 26, 2026 15:10 UTC
-
AI helps surgeons see brain tumors better during surgery
Diagnosis Not yet recruitingIntraoperative ultrasound is a versatile, low-cost imaging tool that has been shown to improve safety and efficacy in brain tumor surgery. However, its widespread adoption remains limited due to operator dependency, the complexity of image interpretation, the presence of artifact…
Phase 3 • Sponsor: Hospital del Rio Hortega • Aim: Diagnosis
Last updated Jun 27, 2026 09:00 UTC
-
Timing is everything: new trial seeks to boost cancer treatment by scheduling immunotherapy just right
Disease control Not yet recruitingThis is a multicenter, open-label, randomized phase II clinical trial designed to evaluate the optimal timing of toripalimab administration during neoadjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. Participants will receive gemcitabine and…
Phase 2 • Sponsor: Fujian Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Engineered immune cells take on tough leukemia in early trial
Disease control Not yet recruitingThe purpose of this clinical trial is to evaluate the safety and efficacy of CAR-ITNK cells therapy targeting CD70 and CLL1 in participants with relapsed/refractory Acute Myeloid Leukemia. Participants will receive a single infusion of CAR-ITNK cell therapy targeting CD70 and CLL…
Early phase 1 • Sponsor: Tongji Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Gene-Edited immune cells take on Hard-to-Treat myeloma in early trial
Disease control PausedThis phase Ib trial tests the safety, side effects and best dose of clustered regularly interspaced short palindromic repeats (CRISPR) delivered anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cells (1XX BCMA CAR-T cells) in treating patients with multiple…
Phase 1 • Sponsor: Thomas Martin, MD • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Could stem cell particles restore hearing? new trial begins.
Disease control Not yet recruitingThe goal of this clinical trial is to learn if small extracellular vesicles derived from mesenchymal stem cells work to treat severe and above sudden sensorineural hearing loss. It will also learn about the safety of small extracellular vesicles. The main questions it aims to ans…
Phase 1/2 • Sponsor: The Affiliated Hospital of Qingdao University • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New drug duo aims to extend remission in advanced ovarian cancer
Disease control Not yet recruitingThis is a single-arm, open-label, multicenter exploratory clinical study designed to evaluate the efficacy and safety of fluzoparib combined with famitinib malate as maintenance therapy in patients with newly diagnosed advanced (FIGO III-IV) high-grade serous or endometrioid ovar…
Phase 2 • Sponsor: Jinhua Zhou • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New hope for transplant patients: shorter drug course may beat stubborn virus
Disease control Recruiting nowTo comparing the efficacy of different durations of Maribavir treatment regimens in patients suffering from refractory CMV infection after allo-HSCT.
Phase 3 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New hope for advanced cervical cancer: drug combo trial launches
Disease control Not yet recruitingThis is a Randomized, Open-Label, Controlled, Multicenter Phase III Clinical Study to evaluate the efficacy of WX390 in combination with toripalimab versus investigator's choice of therapy in patients with recurrent or metastatic cervical cancer who have failed at least one prior…
Phase 3 • Sponsor: Shanghai Jiatan Pharmatech Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New drug duo targets hard-to-treat KRAS G12D cancers
Disease control Recruiting nowThis is a multicenter, open-label, Phase Ib/II clinical study. The study includes Phase Ib-Dose Exploration Stage and Phase II - Efficacy Exploration and Determination Stage.
Phase 1/2 • Sponsor: InxMed (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC